News & Presentations

News Releases

Tarsus Added to NASDAQ Biotechnology Index
Dec 16, 2022
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
Dec 15, 2022
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
Nov 09, 2022
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
Oct 25, 2022
Tarsus Announces Transition Plans for Board of Directors
Oct 11, 2022
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
Oct 06, 2022
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
Sep 29, 2022
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
Sep 27, 2022
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
Sep 07, 2022
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
Aug 11, 2022

Presentations